Emerging Antiviral Strategies to Interfere with Influenza Virus Entry
Identifieur interne : 000770 ( Main/Exploration ); précédent : 000769; suivant : 000771Emerging Antiviral Strategies to Interfere with Influenza Virus Entry
Auteurs : Evelien Vanderlinden [Belgique] ; Lieve Naesens [Belgique]Source :
- Medicinal Research Reviews [ 0198-6325 ] ; 2014-03.
Abstract
Influenza A and B viruses are highly contagious respiratory pathogens with a considerable medical and socioeconomical burden and known pandemic potential. Current influenza vaccines require annual updating and provide only partial protection in some risk groups. Due to the global spread of viruses with resistance to the M2 proton channel inhibitor amantadine or the neuraminidase inhibitor oseltamivir, novel antiviral agents with an original mode of action are urgently needed. We here focus on emerging options to interfere with the influenza virus entry process, which consists of the following steps: attachment of the viral hemagglutinin to the sialylated host cell receptors, endocytosis, M2‐mediated uncoating, low pH‐induced membrane fusion, and, finally, import of the viral ribonucleoprotein into the nucleus. We review the current functional and structural insights in the viral and cellular components of this entry process, and the diverse antiviral strategies that are being explored. This encompasses small molecule inhibitors as well as macromolecules such as therapeutic antibodies. There is optimism that at least some of these innovative concepts to block influenza virus entry will proceed from the proof of concept to a more advanced stage. Special attention is therefore given to the challenging issues of influenza virus (sub)type‐dependent activity or potential drug resistance.
Url:
DOI: 10.1002/med.21289
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000E80
- to stream Istex, to step Curation: 000E80
- to stream Istex, to step Checkpoint: 000034
- to stream Main, to step Merge: 000771
- to stream Main, to step Curation: 000770
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Emerging Antiviral Strategies to Interfere with Influenza Virus Entry</title><author><name sortKey="Vanderlinden, Evelien" sort="Vanderlinden, Evelien" uniqKey="Vanderlinden E" first="Evelien" last="Vanderlinden">Evelien Vanderlinden</name></author><author><name sortKey="Naesens, Lieve" sort="Naesens, Lieve" uniqKey="Naesens L" first="Lieve" last="Naesens">Lieve Naesens</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:8A2E101BD3424E23F1869911292DF0D6C283760C</idno><date when="2014" year="2014">2014</date><idno type="doi">10.1002/med.21289</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-94BKFDHJ-9/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000E80</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000E80</idno><idno type="wicri:Area/Istex/Curation">000E80</idno><idno type="wicri:Area/Istex/Checkpoint">000034</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000034</idno><idno type="wicri:doubleKey">0198-6325:2014:Vanderlinden E:emerging:antiviral:strategies</idno><idno type="wicri:Area/Main/Merge">000771</idno><idno type="wicri:Area/Main/Curation">000770</idno><idno type="wicri:Area/Main/Exploration">000770</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Emerging Antiviral Strategies to Interfere with Influenza Virus Entry</title><author><name sortKey="Vanderlinden, Evelien" sort="Vanderlinden, Evelien" uniqKey="Vanderlinden E" first="Evelien" last="Vanderlinden">Evelien Vanderlinden</name><affiliation wicri:level="1"><country xml:lang="fr">Belgique</country><wicri:regionArea>Rega Institute for Medical Research, KU Leuven, Leuven</wicri:regionArea><wicri:noRegion>Leuven</wicri:noRegion></affiliation></author><author><name sortKey="Naesens, Lieve" sort="Naesens, Lieve" uniqKey="Naesens L" first="Lieve" last="Naesens">Lieve Naesens</name><affiliation wicri:level="1"><country xml:lang="fr">Belgique</country><wicri:regionArea>Rega Institute for Medical Research, KU Leuven, Leuven</wicri:regionArea><wicri:noRegion>Leuven</wicri:noRegion></affiliation><affiliation wicri:level="1"><country wicri:rule="url">Belgique</country></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Medicinal Research Reviews</title><title level="j" type="alt">MEDICINAL RESEARCH REVIEWS</title><idno type="ISSN">0198-6325</idno><idno type="eISSN">1098-1128</idno><imprint><biblScope unit="vol">34</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="301">301</biblScope><biblScope unit="page" to="339">339</biblScope><biblScope unit="page-count">39</biblScope><date type="published" when="2014-03">2014-03</date></imprint><idno type="ISSN">0198-6325</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0198-6325</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract">Influenza A and B viruses are highly contagious respiratory pathogens with a considerable medical and socioeconomical burden and known pandemic potential. Current influenza vaccines require annual updating and provide only partial protection in some risk groups. Due to the global spread of viruses with resistance to the M2 proton channel inhibitor amantadine or the neuraminidase inhibitor oseltamivir, novel antiviral agents with an original mode of action are urgently needed. We here focus on emerging options to interfere with the influenza virus entry process, which consists of the following steps: attachment of the viral hemagglutinin to the sialylated host cell receptors, endocytosis, M2‐mediated uncoating, low pH‐induced membrane fusion, and, finally, import of the viral ribonucleoprotein into the nucleus. We review the current functional and structural insights in the viral and cellular components of this entry process, and the diverse antiviral strategies that are being explored. This encompasses small molecule inhibitors as well as macromolecules such as therapeutic antibodies. There is optimism that at least some of these innovative concepts to block influenza virus entry will proceed from the proof of concept to a more advanced stage. Special attention is therefore given to the challenging issues of influenza virus (sub)type‐dependent activity or potential drug resistance.</div></front></TEI><affiliations><list><country><li>Belgique</li></country></list><tree><country name="Belgique"><noRegion><name sortKey="Vanderlinden, Evelien" sort="Vanderlinden, Evelien" uniqKey="Vanderlinden E" first="Evelien" last="Vanderlinden">Evelien Vanderlinden</name></noRegion><name sortKey="Naesens, Lieve" sort="Naesens, Lieve" uniqKey="Naesens L" first="Lieve" last="Naesens">Lieve Naesens</name><name sortKey="Naesens, Lieve" sort="Naesens, Lieve" uniqKey="Naesens L" first="Lieve" last="Naesens">Lieve Naesens</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000770 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000770 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= H2N2V1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:8A2E101BD3424E23F1869911292DF0D6C283760C
|texte= Emerging Antiviral Strategies to Interfere with Influenza Virus Entry
}}
| This area was generated with Dilib version V0.6.33. |  |